208 related articles for article (PubMed ID: 32777557)
1. Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer.
Harada H; Soeno T; Yokoi K; Nishizawa N; Ushiku H; Hosoda K; Hiki N; Yamashita K
J Surg Res; 2020 Dec; 256():404-412. PubMed ID: 32777557
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy.
Yokoi K; Harada H; Yokota K; Ishii S; Tanaka T; Nishizawa N; Shimazu M; Kojo K; Miura H; Yamanashi T; Sato T; Nakamura T; Watanabe M; Yamashita K
Ann Surg Oncol; 2019 Feb; 26(2):406-414. PubMed ID: 30311169
[TBL] [Abstract][Full Text] [Related]
3. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
Harada H; Hosoda K; Moriya H; Mieno H; Ema A; Ushiku H; Washio M; Nishizawa N; Ishii S; Yokota K; Tanaka Y; Kaida T; Soeno T; Kosaka Y; Watanabe M; Yamashita K
PLoS One; 2019; 14(4):e0214872. PubMed ID: 30934021
[TBL] [Abstract][Full Text] [Related]
4. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
[TBL] [Abstract][Full Text] [Related]
6. DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer.
Ushiku H; Yamashita K; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Katoh H; Watanabe M
Gastric Cancer; 2017 Sep; 20(5):784-792. PubMed ID: 28243814
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
[TBL] [Abstract][Full Text] [Related]
8. Prospective study to validate the clinical utility of DNA diagnosis of peritoneal fluid cytology test in gastric cancer.
Harada H; Soeno T; Nishizawa N; Washio M; Sakuraya M; Ushiku H; Niihara M; Hosoda K; Kumamoto Y; Naitoh T; Sangai T; Hiki N; Yamashita K
Cancer Sci; 2021 Apr; 112(4):1644-1654. PubMed ID: 33576114
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of the novel tumor suppressor cysteine dioxygenase 1 in esophageal squamous cell carcinoma.
Kwon J; Park M; Kim JH; Lee HW; Kang MC; Park JH
Tumour Biol; 2015 Sep; 36(10):7449-56. PubMed ID: 25903467
[TBL] [Abstract][Full Text] [Related]
10. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
Deckers IA; Schouten LJ; Van Neste L; van Vlodrop IJ; Soetekouw PM; Baldewijns MM; Jeschke J; Ahuja N; Herman JG; van den Brandt PA; van Engeland M
Clin Cancer Res; 2015 Aug; 21(15):3492-500. PubMed ID: 25904753
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
12. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
[TBL] [Abstract][Full Text] [Related]
13. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
Ushiku H; Yamashita K; Katoh H; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Watanabe M
Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 27629777
[TBL] [Abstract][Full Text] [Related]
14. Differential Prognostic Relevance of Promoter DNA Methylation of
Tanaka Y; Kosaka Y; Waraya M; Yokota K; Harada H; Kaida T; Kikuchi M; Minatani N; Nishimiya H; Katoh H; Sengoku N; Watanabe M; Yamashita K
Anticancer Res; 2019 May; 39(5):2289-2298. PubMed ID: 31092420
[TBL] [Abstract][Full Text] [Related]
15. Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers.
Brait M; Ling S; Nagpal JK; Chang X; Park HL; Lee J; Okamura J; Yamashita K; Sidransky D; Kim MS
PLoS One; 2012; 7(9):e44951. PubMed ID: 23028699
[TBL] [Abstract][Full Text] [Related]
16. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
17. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer.
Zhang LH; Wang Y; Fan QQ; Liu YK; Li LH; Qi XW; Mao Y; Hua D
World J Gastroenterol; 2019 Oct; 25(38):5814-5825. PubMed ID: 31636474
[TBL] [Abstract][Full Text] [Related]
18. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
[TBL] [Abstract][Full Text] [Related]
19. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH
Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987
[TBL] [Abstract][Full Text] [Related]
20. CD33+ Immature Myeloid Cells Critically Predict Recurrence in Advanced Gastric Cancer.
Soeno T; Katoh H; Ishii S; Ushiku H; Hosoda K; Hiki N; Watanabe M; Yamashita K
J Surg Res; 2020 Jan; 245():552-563. PubMed ID: 31472311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
